Loading data for NPCE — first visit, this takes a few seconds.

Alert

NeuroPace Inc. (NPCE)

NasdaqGM: NPCE · Real-Time Price · USD

14.03

+0.01 (0.07%)

At close: Aug 21, 2026, 8:00 PM

14.03

+0.00%

After-hours: 7:30 PM

The price, the headline numbers and the latest news, in one place.

0.07% (1D)

No data available

Bid	10.16
Market Cap	481.57M
Revenue (ttm)	106.99M
Net Income (ttm)	-16.17M
	1.94
	-0.47
	n/a
	-63.15
P/B (ttm)	40.43
P/S (ttm)	4.50
Earnings Date	Nov 3, 2026

Ask	17.12
Volume	115,977
Avg. Volume (20D)	189,519
Open	14.14
Previous Close	14.02
Day's Range	13.87 - 14.20
52-Week Range	8.61 - 19.60
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the co...

[Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Apr 22, 2021

Employees 220

Stock Exchange NasdaqGM

Ticker Symbol NPCE

Website https://www.neuropace.com

Full Company Profile

Financial Performance

In 2025, NeuroPace's revenue was 99.99M, an increase of 25.13% compared to the previous year's 79.91M. Earnings were -21.46M, a decrease of -20.91%.

Financial Statements

Earnings Surprise

NeuroPace has released their quarterly earnings on Aug 11, 2026:

Revenue of $22.07M misses estimates by $0, with -2.02% YoY decline.
EPS of -0.18 exceeds estimates by 0.01, with 14.29% YoY growth.

Next Earnings Release

NeuroPace Inc. is scheduled to release its earnings on Nov 3, 2026, during market hours.
Analysts project revenue of ... Upgrade

News

4 days ago · GuruFocus.com

NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...

NeuroPace Inc (NPCE) raises full-year guidance on 21.3% RNS revenue growth, while navigating an unexpected FDA request for additional IGE data.

6 days ago · Zacks

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

6 days ago · Zacks

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

6 days ago · Zacks

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

1 week ago · Zacks

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

Page 1 of 2

NeuroPace Inc. (NPCE)